Juan Carlos Lacal

Juan Carlos Lacal Sanjuán is a Spanish biologist, biochemist, inventor and academic. He is a professor of Research at the Sols-Morreale Biomedical Research Institute, which is run by the Spanish National Research Council (CSIC) and the Autonomous University of Madrid (UAM).

Lacal's research focuses on translational oncology and precision medicine. He is the recipient of the 1992 Salud 2000 Foundation Research Prize, the 1997 Best Communication Award from the European Association for Cancer Research (EACR), and the Antonio Esteve Foundation Research Award in 1999.

Education and early career Lacal earned bachelor's and master's degrees in Biology, Biochemistry and Molecular Biology in 1979 and a Ph.D. in Biochemistry and Molecular Biology in 1982, all from the Autonomous University of Madrid. He held postdoctoral fellowships funded by the European Molecular Biology Organization (Jan 1983 to Dec 1984), and the Fogarty International Center at NIH (Jan 1985 to Dec 1986) at the Laboratory of Cellular and Molecular Biology, National Cancer Institute. Subsequently, he became a member of the Council of the Federation of European Cancer Societies (FECS) and its executive committee in 1997–2000. In 2005, he assumed the position of vice-president of Research and President of the Scientific Advisory Board at TCD Pharma until 2010. He was appointed as a member (1996-2011) and President (2012-2013) of the Council of the European Association for Cancer Research (EACR). He took on the position of deputy director of Translational Oncology at the Jiménez Díaz Foundation in 2013. In 2017, he worked as a Senior Researcher of Translational and Medical Oncology at the Fuenlabrada University Hospital until 2019. He has been serving as a member of the Lilly Foundation Scientific Council for the MEDES initiative, since 2005 and the Scientific Advisory Board of INCLIVA, the Biomedical Research Institute at the Valencia Clinical Hospital since 2011.

Lacal served as Professor of Research at the CSIC from 2002 until 2013, and has held the position since assuming it again in 2019. He has been involved in the organization of multiple national and international congresses, symposia, and meetings.

Choline kinase alpha and human diseases Lacal and colleagues established a significant association between increased ChoKα activity and overexpression in human lung, prostate, colorectal and breast cancer, thereby suggesting the potential of ChoKα as a target for a novel anti-tumoral strategy in cancer treatment, along with its potential in identifying early stage non-small-cell lung cancer in patients.

Lacal and collaborators worked on developing ChoKα inhibitors to be used as pharmaceutical approaches and demonstrated that this enzyme is a promising drug target for precision medicine approaches against cancer, malaria, rheumatoid arthritis and inflammatory diseases.

Lacal founded Translational Cancer Drugs Pharma S.L. (TCD Pharma SL) in 2005 and Advanced Marker Discovery S.L. (AMADIX S.L.) in 2010. TCD Pharma promoted the first in human Clinical Trial with RSM932A/TCD717, a potent ChoKα inhibitor.

Small GTPases in carcinogenesis Lacal has researched translational oncology throughout his career. In a highly cited collaborative study, he found that the Rho family of GTPases activates the transcription factor NF-kappaB by a mechanism that is independent of Ras and Raf-1 kinases, and that Rho GTPases play a critical role in transcription regulation in the context of carcinogenesis, metastasis, and apoptosis. He also pointed out the evidence indicating that the dysregulation of Rho GTPase signaling is implicated in the process of carcinogenesis, and highlighted the critical role of several members of the small GTPase superfamily in addition to Ras and Rho A, in controlling key cellular signaling functions.

In a study published in Nature, Lacal found that the Ha-ras oncogene activates a novel pathway for 1,2-diacylglycerol production in transformed cells altering the regulation of the phosphatidylcholine biosynthetic pathway. This finding led to the discovery of ChoKα as a biomarker in multiple cancers and a druggable target in a diversity of human pathologies.

Awards 1992 – Research Prize, Salud 2000 Foundation 1997 – Best Communication Award, European Association for Cancer Research 1999 – Research Award, Antonio Esteve Foundation

Selected articles